Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8NA56
UPID:
TTC29_HUMAN
Alternative names:
Protein TBPP2A; Testis development protein NYD-SP14
Alternative UPACC:
Q8NA56; A4GU95; Q9BXB6
Background:
Tetratricopeptide repeat protein 29, also known as Protein TBPP2A or Testis development protein NYD-SP14, plays a crucial role in reproductive biology. It is an axonemal protein essential for the assembly of axonemal and peri-axonemal structures, directly influencing flagella assembly and sperm motility.
Therapeutic significance:
Given its pivotal role in sperm motility, Tetratricopeptide repeat protein 29 is closely associated with Spermatogenic failure 42, a condition marked by severe infertility due to sperm motility issues. Understanding the role of Tetratricopeptide repeat protein 29 could open doors to potential therapeutic strategies for treating infertility disorders.